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(3E,5E)-3,5-bis(3,4-dihydroxybenzylidene)piperidin-4-one hydrochloride (8). 3 7 was synthesized from piperidin-4-one hydrochloride (500 mg, 2.91mmol) and 3,4,dihydroxybenzaldehyde (1210 mg, 8.73 mmol). The precipitate was filtered off and washed with petroleum ether, diethyl ether, ethanol and dichloromethane to give 8 as a green solid: 940 mg (86%), m.p. = 222-225°C. 1 H NMR (400 MHz, DMSO-d 6 ) δ 4.40 (s, 4H), 6.82-6.88 (m, 6H), 7.66 (s, 2H), 9 .41 (br s, 4H), 9.78 (s, 2H) .
(3E,5E)-3,5-bis(4-hydroxybenzylidene)piperidin-4-one hydrochloride (9). 4 9 was synthesized from piperidin-4-one hydrochloride (500 mg, 2.91mmol) and 4-hydroxybenzaldehyde (1066 mg, 8 .73 mmol). The precipitate was filtered off and washed with H 2 O, petroleum ether and dichloromethane to give 9 as a green solid: 680 mg (68%), m.p. = 248-251°C. 1 (3E,5E)-3,5-bis(3-hydroxybenzylidene)piperidin-4-one hydrochloride (10). 4 10 was synthesized from piperidin-4-one hydrochloride (468 mg, 2.73 mmol) and 3-hydroxybenzaldehyde (1000 mg, 8.19 mmol). The precipitate was filtered off and washed with petroleum ether and diethyl ether to afford 9 as a yellow solid: 630 mg (67%). 1 (3E,5E)-3,5-bis(3,4-dimethoxybenzylidene)piperidin-4-one hydrochloride (11). 3 (3E,5E)-3,5-dibenzylidenepiperidin-4-one hydrochloride (12) . 5 General procedure for the intermediates 13-17. To a solution of 7 6 (1 equiv) in dry DMF (2-3 mL) were added PPAA (2 equiv), Et 3 N (3 equiv) and the appropriate intermediates (8-12) (1 equiv) under nitrogen atmosphere. After leaving the reaction to rt overnight, the solvent was evaporated and the crude product purified by column chromatography on silica gel to yield the desired compounds 13-17. General procedure for compounds 2-6. To a stirred solution of the appropriate Boc-compound (13-17) (1 equiv) in CH 2 Cl 2 (5 mL) was carefully added at 0°C trifluoroacetic acid (30% in DCM).
(3-{4-[3,5-Bis-(3,4-dihydroxybenzylidene)-4-oxo-piperidin-1-yl]-4-oxo-butanamido}-propyl)-

{4-[tert-butoxycarbonyl-(3-tert-butoxycarbonylamino-propyl)-amino]-butyl}-carbamic acid
After being stirred at room temperature for 4 hours, the solvent was evaporated under reduced pressure, adding heptane for the azeotropic removal of trifluoroacetic acid traces. The trifluoroacetate salts were washed with ether to obtain 2-6. with and without inhibitor. Blanks containing inhibitor and ThT were also prepared and evaluated to account for quenching and S9 fluorescence properties. The fluorescence intensities were compared and the percentage inhibition was calculated.
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Inhibition of Aβ
Inhibition of Aβ 42 self-aggregation as determined by flow injection ESI-MS. Inhibition studies
were performed by incubating Aβ 42 samples under the assay conditions reported above, with and without the tested inhibitor. All selected compounds were first screened at 10 µM in a 0. The percentage of inhibition was calculated as follow:
ቁ where x ୲ is the Area Aβ42m/Area IS ratio at t= 0, ‫ݔ‬ ௧ଶସ is the Area Aβ42m/Area IS ratio after 24h in the absence of inhibitor and ‫݅ݔ‬ ௧ଶସ is the Area Aβ42m/Area IS ratio after 24h in the presence of S10 inhibitor. The results are expressed as mean ±SD of three independent experiments, and p<0.05 was considered statistically significant (Dunnett's multiple comparison test).
Cultures of mixed cortical neurons and assessment of neuronal injury.
Cultures of pure cortical neurons were obtained from rats at embryonic day 17 (Envigo Laboratories, Italy). Briefly, cortices were dissected in Ca ++ /Mg ++ free buffer and mechanically CGenFF (CHARMM General Force Field) for small molecules. 13 In order to study binding of ligands to Aβ 42 we used helical conformations of amyloid as well as its oligomeric form. The helical structures of Aβ 42 were taken from Protein Data Bank NMR structure (PDB id:1IYT). 14 The first five from ten models deposited in 1IYT were selected to our study. They were distributed circularly with ligand in the center. Helical structures of Aβ 42 were rotated randomly around their long axis, including upside down flipping, to simulate random distribution. The structure of Aβ 42 in oligomeric fibril form, involving five monomers, was also taken as NMR structure from Protein Data Bank (PDB id:2BEG). 15 Since only part of the structure is visible (residues 17-42) the lacking residues were added by incorporating 16-residue fragment from NMR structure of Aβ(1-28) (PDB id:1BJC). 16 The fragment 1-16 exists in the coil form. Different NMR conformations of this 1-16 fragment were selected for each monomer of the fibril. Two identical ligands were inserted at both ends of the fibril, one at each side, in a distance 2.5 Å on average.
Molecular dynamics simulations.
The prepared Aβ 42 -ligand systems were initially subjected to 10 000 steps of energy minimization and then 100 ns MD equilibration with increasing temperature from 20 K to 298 K. All energy minimizations and molecular dynamics (MD) simulations were performed in NAMD program version 2.10 using all-atom force field CHARMM22 17 in implicit solvent. The MD simulations were conducted using Langevin (stochastic) dynamics 18 which is default in the NAMD program. The molecules in the system interact with a stochastic heat bath via random forces and dissipative forces. The friction coefficient of 50 ps -1 was used and temperature was set to 298 K. Non-bonded interactions were damped employing a switching function for van S13 der Waals and electrostatic interactions using cutoff of 14 Å. For each investigated system 600 ns MD simulation was performed with a time step of 2 fs. All bond lengths were constrained using SHAKE algorithm. 19 All figures of molecular structures were created using VMD program and beta-amyloid, mostly hydrogen bonds, involving catechol rings: R5 (mc) and F20 (mc) for one ring, and G33 (mc) with M35 (mc) for the second ring; and also spermine tail: A21 (mc), E22 (sc), D1 (sc), N27 (mc), V24 (mc), N27 (ms). Both copies of compound 2 are perpendicular to β-sheet of amyloid fibril. Compound 8 forms much less of hydrogen bonds than compound 2 at both ends of the fibril: E11 (mc), V36 (mc), E22 (sc), and additionally there is some number of π-π interactions:
H13 (sc), H14 (sc), F20 (sc). At one end of fibril the compound 8 is parallel to β-sheet while at the other end it is perpendicular. Spermine binds to the fibril in extended conformation and creates S14 many hydrogen bonds with main chain and also side chains of amino acids: D1 (sc), F20 (mc), E22
(sc), V24 (sc), S26 (mc), N27 (sc), G37 (mc). S15 Figure S1 . Antioxidant activity of compounds 2 and 3 on oxidative stress induced by tert-Butyl hydroperoxide (TBHP). T67 cells were pretreated for 4 hours with 10µM of compounds 2 and 3.
Figures
After this time, ROS were detected by following DCFDA oxidation after 30 minutes exposure to 100 µM TBHP. Compound 2 and compound 8 were applied to neuronal cultures at increasing concentrations (250 nM-50 µM). The intrinsic toxicity of compounds 2 and 8 was assessed by cell counting after trypan blue staining. Cell counts was performed in three random microscopic fields/well. S19
